SUMMARY
Histone acetyltransferase and histone deacetylase activities determine the acetylation status of histones,
and have the ability to regulate gene expression through chromatin remodeling. A controlled balance
between histone acetylation and histone deacetylation appears to be essential for normal cell growth. In
cancer cells, some genes are repressed by inappropriate recruitment of histone deacetylases. The histone
deacetylase inhibitors (HDACI) belong to the class of anticancer drugs that are effective in killing
proliferating and non-proliferating tumor cells. In this review we discuss molecular mechanisms involved
in the induction of cell cycle arrest, differentiation and induction of apoptosis in tumor cells by HDACI.
KEY WORDS
histone deacetylase inhibitors; apoptosis; cell cycle; chemotherapy
REFERENCES
Beck GR Jr, Zerler B, Moran E: Gene array
analysis of osteoblast differentiation. Cell
Growth Differ 12:61-83, 2001.
Blagosklonny MV, Robey R, Sackett DL et al.:
Histone deacetylase inhibitors all induce p21
but differentially cause tubulin acetylation,
mitotic arrest and cytotoxicity. Mol Cancer
Therap 11:937-941, 2002.
Burgess AJ, Pavey S, Warrener R et al.: Upregulation
of 21waf1/CIP1 by histone deacetylase
inhibitors reduces their cytotoxicity. Mol
Pharmacol 60:828-837, 2001.
Burgess A, Ruefli A, Beamish H et al.: Histone
deacetylase inhibitors specifically kill
nonproliferating tumour cells. Oncogene
23:6693-6701, 2004.
Butler LM, Agus DB, Scher HI et al.:
Suberoylanilide hydroxamic acid, an inhibitor
of histone deacetylase, suppresses the growth
of prostate cancer cells in vitro and in vivo.
Cancer Res 60:5165-5170, 2000.
Caron H, van Schaik B, van der Mee M et al.:
The human transcriptome map: Clustering of
highly expressed genes in chromosomal
domains. Science 291:1289-1292, 2001.
Clausen MR: Butyrate and colorectal cancer in
animals and in humans (mini-symposium:
Butyrate and colorectal cancer). Eur J Cancer
Prev 4:483-490, 1995.
Davie JR: Covalent modifications of histones:
expression from chromatin templates. Curr
Opin Genet Dev 8:173-178, 1998.
de Ruijter AJ, van Gennip AH, Caron HN et al.:
Histone deacetylases (HDACs): characterization of the classical HDAC family.
Biochem J 370:737-749, 2003.
Glaser KB, Staver MJ, Waring JF et al.: Gene
expression profiling of multiple histone
deacetylase (HDAC) inhibitors. Defining a
common gene set produced by HDAC
inhibition in T24 and MDA carcinoma cell
lines. Mol Cancer Ther 2:151-163, 2003.
Gottlicher M: Valproic acid: an old drug newly
discovered as inhibitor of histone deacetylases.
Ann Hematol 83:S91-92, 2004.
Gottlicher M, Minucci S, Zhu P et al.: Valproic
acid defines a novel class of HDAC inhibitors
inducing differentiatiation of transformed cells.
EMBO J 20:6969-6978, 2001.
Gui CY, Ngo L, Xu WS et al.: Histone
deacetylase (HDAC) inhibitor activation of
p21 WAF1 involves changes in promotor-associated
proteins, including HDAC1. PNAS
101:1241-1246, 2004.
Jacobs R: Role of dietary factors in cell replication
and colon cancer. Am J Clin Nutr 48(Suppl. 3):775-779, 1988.
Hofmanova J, Vaculova A, Kozubik A:
Polyunsaturated fatty acids sensitize human
colon adenocarcinoma HT-29 cells to death
receptor-mediated apoptosis. Cancer Lett
218:33-41, 2005.
Kelly WK, Richon VM, O'Connor O et al.:
Phase I clinical trial of histone deacetylase
inhibitor: suberoylanilide hydroxamic acid
administered intravenously. Clin Cancer Res
9:3578-3588, 2003.
Kim YK, Han JW, Woo YN et al.: Expression
of p21 Waf1/Cip1 through Sp1 sites by histone
deacetylase inhibitor apicidin requires PI 3-
kinase-PKCdelta signaling pathway. Oncogene
22:6023-6031, 2003.
Kuendgen A, Strupp C, Aivado M et al.:
Treatment of myelodysplastic syndromes with
valproic acid alone or in combination with all-trans
retinoic acid. Blood 104:1266-1269, 2004.
Leskov KS, Klokov DY, Li J et al.: Synthesis
and functional analyses of nuclear clusterin, a
cell death protein. J Biol Chem 278:11590-11600, 2003.
Luo RX, Dean DC: Chromatin remodeling and
transcriptional regulation. J Natl Cancer Inst
91:1288-1294, 1999.
Luger K, Richmond TJ: The histone tails of the
nucleosome. Curr Opin Genet Dev 8:140-146, 1998.
McIntyre A, Gibson PR, Young GP: Butyrate
production from dietary fibre and protection against large bowel cancer in a rat model. Gut
34:386-391, 1993.
Nebbioso A, Clarke N, Voltz E et al.: Tumor-selective
action of HDAC inhibitors involves
TRAIL induction in acute myeloid leukemia
cells. Nature Med 11:77-84, 2005.
Qiu L, Burgess A, Fairlie DP et al.: Histone
deacetylase inhibitors trigger a G2 checkpoint
in normal cells that is defective in tumor cells.
Mol Biol Cell 11:2069-2083, 2000.
Ragione FD, Criniti V, Pietra VD et al.: Genes
modulated by histone acetylation as new
effectors of butyrate activity. FEBS Lett
499:199-204, 2001.
Richon VM, Sandhoff TW, Rifkind RA et al.:
Histone deacetylase inhibitor selectively
induces p21 WAF1 expression and gene -
associated histone acetylation. PNAS
97:10014-10019, 2000.
Rosato RR, Almenara JA, Yu C et al.:
Simultaneous activation of the intrinsic and
extrinsic pathways by HDAC inhibitors and
TRAIL synergistically induces mitochondrial
damage and apoptosis in human leukemia cells.
Mol Cancer Ther 2:1273-1284, 2003.
Rosato RR, Grant S: Histone deacetylase
inhibitors in clinical development. Expert
Opin Investig Drugs 13:21-38, 2004.
Rosato RR, Almenara JA,Yu C et al.: Evidence
of a functional role for p21 WAF1/Cip1 down-regulation
in synergistic antileukemic
interactions between the histone deacetylase
inhibitor sodium butyrate and flavopiridol.
Mol Pharmacol 65:571-581, 2004.
Suenaga M, Soda H, Oka M et al.: Histone
deacetylase inhibitors suppress telomerase
reverse transcriptase mRNA expression in
prostate cancer cells. Int J Cancer 97:621-625, 2002.
Vrana JA, Decker RH, Johnson CR et al.:
Induction of apoptosis in U 937 human
leukemia cells by suberoylanilide hydroxamic
acid (SAHA) proceeds through pathways that
are regulated by Bcl-2/Bcl-XL, c-Jun, and
p21CIP1, but independent of p53. 0ncogene
18:7016-7025, 1999.
Warrell RP, He LZ, Richon V et al.: Therapeutic
targeting of transcription in acute
promyelocytic leukemia by use of an inhibitor
of histone deacetylase. J Natl Cancer Inst
90:1621-1925, 1998.
Wu JT, Archer SY, Hinnebusch B et al.:
Transient vs. prolonged histone
hyperacetylation: effects on colon cancer cell
growth, differentiation, and apoptosis. Am J
Physiol Gastrointest Liver Physiol
280:G482-G490, 2001.
Yoshida M, Kijima M, Akita M et al.: Potent and
specific inhibition of mammalian histone
deacetylase both in vivo and in vitro by
trichostatin A. J Biol Chem 265:17174-17179, 1990.
Yoshida M, Furumai R, Nishiyama M et al.:
Histone deacetylase as a new target for cancer
chemotherapy. Cancer Chemother Pharmacol
48(Suppl. 11):20-26, 2001.
|
CITED
Sangshetti JN, Sakle NS, Dehghan MHG, Shinde DB. Histone deacetylases as targets for multiple diseases. Mini-Rev Med Chem. 13: 1005-1026, 2013.
Balakin KV, Ivanenkov YA, Kiselyov AS, Tkachenko SE. Histone deacetylase inhibitors in cancer therapy: Latest developments, trends and medicinal chemistry perspective. Anti-Cancer Agents Med Chem. 7: 576-592, 2007.
Rezacova M, Vavrova J, Vokurkova D, Zaskodova D. Effect of valproic acid and antiapoptotic cytokines on differentiation and apoptosis induction of human leukemia cells. General Phys Biophys. 25: 65-79, 2006.
|
